Tuyls Sebastiaan, Van Der Brempt Xavier, Faber Margaretha, Gadisseur Romy, Dezfoulian Bita, Schrijvers Rik, Froidure Antoine
Pulmonology Department, Sint Augustinus Ziekenhuis GZA, Antwerpen and UZ Leuven, Leuven, Belgium.
Pulmonology Department and Allergopôle, Clinique Saint-Luc, Bouge, Belgium.
Acta Clin Belg. 2022 Jun;77(3):552-557. doi: 10.1080/17843286.2021.1909447. Epub 2021 Apr 1.
Vaccination against COVID-19 constitutes a huge hope and a major challenge. For the first time in modern history, a global vaccination campaign has started worldwide in a short period of time and with products that were recently developed. Consequently, legitimate concerns regarding the safety and tolerability of COVID-19 vaccines arise.In line with international allergy societies, the Belgian Society for Allergy and Clinical Immunology (BelSACI) provides this statement to guide health care providers (general practitioners, specialists including allergists) and stakeholders.In this statement, we first review current evidence on allergic reactions to vaccines and the potential risk factors that have been identified.Second, we provide a risk stratification method that may be used as a worksheet during the vaccination campaign.Finally, we discuss the management of suspected or confirmed allergic reactions following vaccination.
接种新冠病毒疫苗带来了巨大希望，也构成了重大挑战。在现代历史上，首次在短时间内针对全球启动了一场使用近期研发产品的全球疫苗接种运动。因此，人们对新冠病毒疫苗的安全性和耐受性产生了合理担忧。比利时过敏与临床免疫学会（BelSACI）与国际过敏学会保持一致，发布本声明以指导医疗保健提供者（全科医生、包括过敏症专科医生在内的专科医生）和利益相关者。在本声明中，我们首先回顾目前关于疫苗过敏反应及已确定的潜在风险因素的证据。其次，我们提供一种风险分层方法，可在疫苗接种运动期间用作工作表。最后，我们讨论接种疫苗后疑似或确诊过敏反应的管理。
